NASDAQ:NBIX - Neurocrine Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $86.53 -3.30 (-3.67 %) (As of 03/22/2019 02:55 PM ET)Previous Close$89.83Today's Range$85.52 - $89.5452-Week Range$64.72 - $126.98Volume557,334 shsAverage Volume823,283 shsMarket Capitalization$7.86 billionP/E Ratio393.32Dividend YieldN/ABeta1.86 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California. Receive NBIX News and Ratings via Email Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX Previous Symbol CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone858-617-7600Debt Debt-to-Equity Ratio0.81 Current Ratio8.36 Quick Ratio8.24Price-To-Earnings Trailing P/E Ratio393.32 Forward P/E Ratio665.62 P/E Growth27.35 Sales & Book Value Annual Sales$451.24 million Price / Sales17.42 Cash Flow$0.5114 per share Price / Cash Flow169.21 Book Value$5.30 per share Price / Book16.33Profitability EPS (Most Recent Fiscal Year)$0.22 Net Income$21.11 million Net Margins4.68% Return on Equity5.06% Return on Assets2.36%Miscellaneous Employees585 Outstanding Shares90,820,000Market Cap$7.86 billion Next Earnings Date4/29/2019 (Estimated) OptionableOptionable Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Tuesday, February, 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.05. The firm had revenue of $131.49 million for the quarter, compared to analysts' expectations of $132.32 million. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. The company's revenue was up 39.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.07 EPS. View Neurocrine Biosciences' Earnings History. When is Neurocrine Biosciences' next earnings date? Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for Neurocrine Biosciences. What price target have analysts set for NBIX? 18 brokerages have issued 12-month price objectives for Neurocrine Biosciences' stock. Their predictions range from $17.07 to $135.00. On average, they anticipate Neurocrine Biosciences' share price to reach $102.5594 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences. What is the consensus analysts' recommendation for Neurocrine Biosciences? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences. What are Wall Street analysts saying about Neurocrine Biosciences stock? Here are some recent quotes from research analysts about Neurocrine Biosciences stock: 1. According to Zacks Investment Research, "Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. " (2/9/2019) 2. HC Wainwright analysts commented, "Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS." (1/30/2019) 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $121 PT on NBIX. Voyager (VYGR, NC) announced a collaboration to develop four of Voyager’s assets, including those for Friedrich’s Ataxia. We believe this deal brings value to both partners, allowing Neurocrine to expand its platform to innovative gene therapy treatments, while it continues to focus on realizing clinical and commercial synergies in movement disorders (and also possibly to expand to additional indications that may be served by Voyager’s platform). We also opine that Voyager benefits from a partner with significantly more resources and expertise in clinical development and commercialization." (1/29/2019) Has Neurocrine Biosciences been receiving favorable news coverage? Media coverage about NBIX stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurocrine Biosciences earned a news impact score of 2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Neurocrine Biosciences' key competitors? Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Aerie Pharmaceuticals (AERI). What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Celgene (CELG), Sarepta Therapeutics (SRPT), Netflix (NFLX), Exelixis (EXEL) and Intel (INTC). Who are Neurocrine Biosciences' key executives? Neurocrine Biosciences' management team includes the folowing people: Dr. Kevin C. Gorman, CEO & Director (Age 61)Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62) Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (5.07%), BB Biotech AG (3.69%), First Trust Advisors LP (1.43%), Geode Capital Management LLC (1.00%), Geode Capital Management LLC (1.00%) and Norges Bank (0.94%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences. Which institutional investors are selling Neurocrine Biosciences stock? NBIX stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Millennium Management LLC, Perceptive Advisors LLC, Public Employees Retirement Association of Colorado, Columbus Circle Investors, Victory Capital Management Inc., Braun Stacey Associates Inc. and Frontier Capital Management Co. LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Corinne H Nevinny, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Insider Buying and Selling for Neurocrine Biosciences. Which institutional investors are buying Neurocrine Biosciences stock? NBIX stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Orbimed Advisors LLC, Thrivent Financial for Lutherans, First Trust Advisors LP, GW&K Investment Management LLC, BB Biotech AG, American Century Companies Inc. and Westfield Capital Management Co. LP. View Insider Buying and Selling for Neurocrine Biosciences. How do I buy shares of Neurocrine Biosciences? Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $86.53. How big of a company is Neurocrine Biosciences? Neurocrine Biosciences has a market capitalization of $7.86 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe. What is Neurocrine Biosciences' official website? The official website for Neurocrine Biosciences is http://www.neurocrine.com. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected] MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)Community Ranking: 3.9 out of 5 ( )Outperform Votes: 753 (Vote Outperform)Underperform Votes: 207 (Vote Underperform)Total Votes: 960MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?